The Zacks Medical sector has modestly outperformed the S&P 500 over the last three months, up more than 7% vs. the general market's 4% gain.
Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.
No one can say whether that will happen next year, but even if it doesn't, there are plenty of companies that can deliver excellent returns despite heightened market volatility and a struggling economy. Let's consider two examples: Eli Lilly (NYSE: LLY) and Visa (NYSE: V). Pharma giant Eli Lilly has been flying high all year despite its financial results not being particularly impressive.